相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
Lynda Vuong et al.
CANCER RESEARCH (2019)
Role of Galectins in Tumors and in Clinical Immunotherapy
Feng-Cheng Chou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration
Monica Gordon-Alonso et al.
NATURE COMMUNICATIONS (2017)
IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma
Sara M. Melief et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Predictive relevance of PD-L1 expression combined with CD8+TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
Takaaki Tokito et al.
EUROPEAN JOURNAL OF CANCER (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments
Ana Carolina Ferreira Cardoso et al.
FRONTIERS IN ONCOLOGY (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages
Ruder Novak et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation
Gabriel A. Rabinovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death
Marta A. Toscano et al.
NATURE IMMUNOLOGY (2007)
Galectins as modulators of tumour progression
FT Liu et al.
NATURE REVIEWS CANCER (2005)
Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions
A Bartolazzi et al.
LANCET (2001)
Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation
M Demetriou et al.
NATURE (2001)
分享论文
